Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00735553 | Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 77 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00444379 | Anti-Retrovirals for Kaposi's Sarcoma(ARKS) | completed | Phase 4 | 224 | University of California, San FranciscoOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00882258 | Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | completed | Phase 2 | 144 | Repros Therapeutics Inc.INDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00874029 | Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids(Halt) | completed | N/A | 137 | Acessa Health, Inc.INDUSTRY | 3 | Jul 3, 2014 | clinicaltrials |
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | withdrawn | Phase 3 | 0 | Repros Therapeutics Inc.INDUSTRY | 2 | Jun 27, 2014 | clinicaltrials |
| NCT00408655 | Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00937495 | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 5, 2014 | clinicaltrials |
| NCT00330421 | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT01631903 | Extension of Study ZPV-200 | completed | Phase 2 | 48 | Repros Therapeutics Inc.INDUSTRY | 1 | Apr 16, 2014 | clinicaltrials |
| NCT01739621 | Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 0 | Apr 16, 2014 | clinicaltrials |
| NCT01491594 | Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | terminated | Phase 1 | 1 | Duke UniversityOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00485355 | Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy | completed | N/A | 27 | The Cleveland ClinicOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00768742 | Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study(FAST) | withdrawn | N/A | 0 | GynesonicsINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00359333 | Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST(STS) | completed | Phase 2 | 58 | National Health Research Institutes, TaiwanOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00929903 | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00753688 | Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy(PALETTE) | completed | Phase 3 | 369 | GlaxoSmithKlineINDUSTRY | 13 | Aug 22, 2013 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01095926 | Pharmacokinetic Study of Doxorubicin in Children With Cancer(Doxo) | completed | Phase 2 | 101 | University Hospital MuensterOTHER | 4 | Jun 28, 2013 | clinicaltrials |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 27, 2013 | clinicaltrials |
| NCT01112800 | Markers of Anthracycline-Related Cardiac Muscle Injury | withdrawn | — | 0 | St. Jude Children's Research HospitalOTHER | 0 | Jun 19, 2013 | clinicaltrials |
| NCT00003958 | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma | completed | Phase 3 | 702 | Children's Oncology GroupNETWORK | 1 | Jun 17, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00064142 | Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00077454 | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00064324 | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087074 | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01830153 | RAD001 in Advanced Sarcoma | completed | Phase 2 | 41 | Asan Medical CenterOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00864032 | Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall | completed | Phase 1 / Phase 2 | 8 | University of California, DavisOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00098579 | Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT01812018 | Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma | unknown | Phase 2 | 30 | Peng YuanUNKNOWN | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01806350 | Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors | completed | N/A | 40 | New Mexico Cancer Research AllianceOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT01136499 | Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure(ESTIM-LBH) | completed | Phase 2 | 53 | Centre Leon BerardOTHER | 1 | Mar 6, 2013 | clinicaltrials |
| NCT00084630 | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | completed | Phase 2 | 216 | TakedaINDUSTRY | 1 | Jan 21, 2013 | clinicaltrials |
| NCT00025363 | Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2014source: clinicaltrials